首页 > 最新文献

Molecular and clinical oncology最新文献

英文 中文
Risk factors for the lateral cervical lymph node metastasis of papillary thyroid carcinoma: A clinical study. 甲状腺乳头状癌颈侧淋巴结转移危险因素的临床研究。
IF 1.2 Q3 Medicine Pub Date : 2023-04-01 DOI: 10.3892/mco.2023.2621
Takashi Masui, Shiori Adachi, Hirokazu Uemura, Takahiro Kimura, Tadashi Kitahara

Currently, there is a lack of evidence-based risk factors for the lateral cervical lymph node metastasis of papillary thyroid carcinoma (PTC). Thus, the risk factors and recurrence rate of lateral cervical lymph node metastasis were investigated in the present study for patients with PTC who underwent initial radical surgery. The data of 274 patients with PTC who underwent initial radical surgery over a 10-year period from January, 2009 to December, 2018 were retrospectively analyzed. By applying univariate analysis, lymphovascular invasion, venous invasion, extrathyroidal infiltration, paratracheal lymph node metastasis and tumor size were designated as significant risk factors for lateral cervical lymph node metastasis. As regards multivariate analysis, paratracheal lymph node metastasis and tumor size were identified as independent risk factors. The recurrence rate was higher in patients presenting with lateral cervical lymph node metastasis, and the disease-free survival rate was significantly lower in the patient group presenting with lateral cervical lymph node metastasis. On the whole, the present study demonstrated that paratracheal lymph node metastasis and tumor size were independent risk factors for lateral cervical lymph node metastasis.

目前,缺乏基于证据的甲状腺乳头状癌(PTC)侧颈淋巴结转移的危险因素。因此,本研究探讨了PTC患者首次根治性手术后颈侧淋巴结转移的危险因素及复发率。回顾性分析2009年1月至2018年12月10年间接受初始根治性手术的274例PTC患者的数据。通过单因素分析,确定淋巴血管浸润、静脉浸润、甲状腺外浸润、气管旁淋巴结转移和肿瘤大小是颈外侧淋巴结转移的重要危险因素。在多因素分析中,气管旁淋巴结转移和肿瘤大小是独立的危险因素。伴有颈外侧淋巴结转移的患者复发率较高,伴有颈外侧淋巴结转移的患者无病生存率明显较低。综上所述,本研究表明气管旁淋巴结转移和肿瘤大小是颈侧淋巴结转移的独立危险因素。
{"title":"Risk factors for the lateral cervical lymph node metastasis of papillary thyroid carcinoma: A clinical study.","authors":"Takashi Masui,&nbsp;Shiori Adachi,&nbsp;Hirokazu Uemura,&nbsp;Takahiro Kimura,&nbsp;Tadashi Kitahara","doi":"10.3892/mco.2023.2621","DOIUrl":"https://doi.org/10.3892/mco.2023.2621","url":null,"abstract":"<p><p>Currently, there is a lack of evidence-based risk factors for the lateral cervical lymph node metastasis of papillary thyroid carcinoma (PTC). Thus, the risk factors and recurrence rate of lateral cervical lymph node metastasis were investigated in the present study for patients with PTC who underwent initial radical surgery. The data of 274 patients with PTC who underwent initial radical surgery over a 10-year period from January, 2009 to December, 2018 were retrospectively analyzed. By applying univariate analysis, lymphovascular invasion, venous invasion, extrathyroidal infiltration, paratracheal lymph node metastasis and tumor size were designated as significant risk factors for lateral cervical lymph node metastasis. As regards multivariate analysis, paratracheal lymph node metastasis and tumor size were identified as independent risk factors. The recurrence rate was higher in patients presenting with lateral cervical lymph node metastasis, and the disease-free survival rate was significantly lower in the patient group presenting with lateral cervical lymph node metastasis. On the whole, the present study demonstrated that paratracheal lymph node metastasis and tumor size were independent risk factors for lateral cervical lymph node metastasis.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/de/54/mco-18-04-02621.PMC9995565.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9102683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Whole‑body MRI for metastatic workup in patients diagnosed with cancer. 全身MRI用于癌症患者的转移性检查。
IF 1.2 Q3 Medicine Pub Date : 2023-04-01 DOI: 10.3892/mco.2023.2629
Rezheen J Rashid, Soran H Tahir, Fahmi H Kakamad, Sami S Omar, Abdulwahid M Salih, Shaho F Ahmed, Shalaw H Abdalla, Sharo Naqar, Rawezh Q Salih, Suhaib H Kakamad, Karukh K Mohammed, Shevan M Mustafa, Marwan N Hassan, Shvan H Mohammed

Early diagnosis and appropriate staging workup are crucial for cancer patients. Whole-body magnetic resonance imaging (WB-MRI) has been proposed as another practical whole-body approach for assessing local invasiveness and distant metastases in patients newly diagnosed with cancer. The current study aimed to evaluate the efficacy of WB-MRI in assessing metastasis in patients newly diagnosed with cancer using histopathologic data as the reference method. A prospective observational study was performed from April 2018 to July 2020. MRI sequences were utilized to acquire anatomical and functional images in three orthogonal planes. The discovery was classified as nodal, skeletal and visceral metastases. Patient-based analysis was used for visceral metastasis and region-based for skeletal, systemic and lymph node metastases. A total of 43 consecutive patients (mean age, 56±15.2 years) were assessed successively. In 41 patients, there was a concordance between the WB-MRI and histological confirmation. The most prevalent site of metastasis was the skeletal system (18 patients). There were 12 individuals with liver metastasis, 10 with lung metastasis and 4 with peritoneal metastasis, with just one brain metastatic lesion found. On WB-MRI, 38 lymph node groups were deemed positive. Out of the total, 66 skeletal locations contained metastases. The accuracy of WB-MRI for nodal, skeletal and visceral metastases was (98.45, 100 and 100%, respectively). In conclusion, WB-MRI in three orthogonal planes, including the diffusion-weighted MRI with background body signal suppression sequence, may be utilized efficiently and accurately for assessing metastasis staging and may thus be utilized in patients with newly diagnosed cancer.

早期诊断和适当的分期检查对癌症患者至关重要。全身磁共振成像(WB-MRI)已被提出作为评估新诊断癌症患者局部侵袭和远处转移的另一种实用的全身方法。本研究旨在以组织病理学资料为参考,评价WB-MRI对新诊断癌症患者转移的评估效果。一项前瞻性观察研究于2018年4月至2020年7月进行。MRI序列在三个正交平面上获得解剖和功能图像。这一发现被分类为淋巴结转移、骨骼转移和内脏转移。以患者为基础的分析用于内脏转移,以区域为基础的分析用于骨骼、全身和淋巴结转移。连续对43例患者(平均年龄56±15.2岁)进行评估。在41例患者中,WB-MRI与组织学证实相符。最常见的转移部位是骨骼系统(18例)。肝转移12例,肺转移10例,腹膜转移4例,脑转移1例。在WB-MRI上,38组淋巴结被认为是阳性的。其中,66个骨骼部位有转移灶。淋巴结转移、骨骼转移和内脏转移的WB-MRI准确率分别为98.45%、100%和100%。综上所述,包括具有背景体信号抑制序列的弥散加权MRI在内的三个正交平面的WB-MRI可有效准确地用于评估转移分期,从而可用于新诊断的癌症患者。
{"title":"Whole‑body MRI for metastatic workup in patients diagnosed with cancer.","authors":"Rezheen J Rashid,&nbsp;Soran H Tahir,&nbsp;Fahmi H Kakamad,&nbsp;Sami S Omar,&nbsp;Abdulwahid M Salih,&nbsp;Shaho F Ahmed,&nbsp;Shalaw H Abdalla,&nbsp;Sharo Naqar,&nbsp;Rawezh Q Salih,&nbsp;Suhaib H Kakamad,&nbsp;Karukh K Mohammed,&nbsp;Shevan M Mustafa,&nbsp;Marwan N Hassan,&nbsp;Shvan H Mohammed","doi":"10.3892/mco.2023.2629","DOIUrl":"https://doi.org/10.3892/mco.2023.2629","url":null,"abstract":"<p><p>Early diagnosis and appropriate staging workup are crucial for cancer patients. Whole-body magnetic resonance imaging (WB-MRI) has been proposed as another practical whole-body approach for assessing local invasiveness and distant metastases in patients newly diagnosed with cancer. The current study aimed to evaluate the efficacy of WB-MRI in assessing metastasis in patients newly diagnosed with cancer using histopathologic data as the reference method. A prospective observational study was performed from April 2018 to July 2020. MRI sequences were utilized to acquire anatomical and functional images in three orthogonal planes. The discovery was classified as nodal, skeletal and visceral metastases. Patient-based analysis was used for visceral metastasis and region-based for skeletal, systemic and lymph node metastases. A total of 43 consecutive patients (mean age, 56±15.2 years) were assessed successively. In 41 patients, there was a concordance between the WB-MRI and histological confirmation. The most prevalent site of metastasis was the skeletal system (18 patients). There were 12 individuals with liver metastasis, 10 with lung metastasis and 4 with peritoneal metastasis, with just one brain metastatic lesion found. On WB-MRI, 38 lymph node groups were deemed positive. Out of the total, 66 skeletal locations contained metastases. The accuracy of WB-MRI for nodal, skeletal and visceral metastases was (98.45, 100 and 100%, respectively). In conclusion, WB-MRI in three orthogonal planes, including the diffusion-weighted MRI with background body signal suppression sequence, may be utilized efficiently and accurately for assessing metastasis staging and may thus be utilized in patients with newly diagnosed cancer.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/68/9f/mco-18-04-02629.PMC10011947.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9125236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clinical effect of surgical resection on primary malignant and invasive bone tumours of the proximal fibula. 腓骨近端原发性恶性及侵袭性骨肿瘤手术切除的临床疗效。
IF 1.2 Q3 Medicine Pub Date : 2023-04-01 DOI: 10.3892/mco.2023.2623
Feifei Pu, Yihan Yu, Zhicai Zhang, Jianxiang Liu, Zengwu Shao, Fengxia Chen, Jing Feng

There is no unified surgical plan for fibular proximal malignant tumours; therefore, the present study retrospectively analysed the medical records of 19 patients with primary malignant and invasive tumours in the proximal fibula and discussed the postoperative oncological results, complications and postoperative functions of limb salvage surgery. According to pathological classification, there were 10 osteosarcoma cases, 3 chondrosarcoma cases, 2 invasive giant cell osteosarcoma tumour cases, 1 epithelioid sarcoma case, 1 leiomyosarcoma case, 1 fibrosarcoma case and 1 lymphoma case. According to the Enneking instalment, IB stage was found in 2 cases, IIA in 2 cases and IIB in 15 cases. A total of 3 patients underwent Malawer I resection, and 16 patients underwent Malawer II resection. The follow-up period was 11-174 months, with an average of 76.58 months. Local recurrence occurred in three patients and distant metastasis in seven patients; 4 patients succumbed and 15 survived. After biceps femoris tendon reconstruction and lateral collateral ligament insertion, 18 patients had good knee stability. The Musculoskeletal Tumour Society scale ranged between 23 and 29 points, with an average of 27.26 points; the Lysholm Knee Score was 65-84 points, with an average of 83 points. After the resection of proximal fibula primary and invasive tumours, the biceps femoris tendon and lateral collateral ligament insertion point was reconstructed. The data show that this technique can effectively reconstruct stability and restore knee function.

腓骨近端恶性肿瘤没有统一的手术方案;因此,本研究回顾性分析了19例腓骨近端原发性恶性及侵袭性肿瘤患者的病历,并对保肢手术的术后肿瘤结果、并发症及术后功能进行了探讨。按病理分类,骨肉瘤10例,软骨肉瘤3例,侵袭性巨细胞骨肉瘤肿瘤2例,上皮样肉瘤1例,平滑肌肉瘤1例,纤维肉瘤1例,淋巴瘤1例。根据Enneking分期,IB期2例,IIA期2例,IIB期15例。Malawer I切除3例,Malawer II切除16例。随访11 ~ 174个月,平均76.58个月。局部复发3例,远处转移7例;死亡4例,存活15例。经股二头肌肌腱重建及外侧副韧带置入后,18例患者膝关节稳定性良好。肌肉骨骼肿瘤协会的评分范围在23到29分之间,平均27.26分;Lysholm膝关节评分为65-84分,平均为83分。切除腓骨近端原发性及侵袭性肿瘤后,重建股二头肌肌腱及外侧副韧带止点。结果表明,该技术能有效地重建膝关节稳定性,恢复膝关节功能。
{"title":"Clinical effect of surgical resection on primary malignant and invasive bone tumours of the proximal fibula.","authors":"Feifei Pu,&nbsp;Yihan Yu,&nbsp;Zhicai Zhang,&nbsp;Jianxiang Liu,&nbsp;Zengwu Shao,&nbsp;Fengxia Chen,&nbsp;Jing Feng","doi":"10.3892/mco.2023.2623","DOIUrl":"https://doi.org/10.3892/mco.2023.2623","url":null,"abstract":"<p><p>There is no unified surgical plan for fibular proximal malignant tumours; therefore, the present study retrospectively analysed the medical records of 19 patients with primary malignant and invasive tumours in the proximal fibula and discussed the postoperative oncological results, complications and postoperative functions of limb salvage surgery. According to pathological classification, there were 10 osteosarcoma cases, 3 chondrosarcoma cases, 2 invasive giant cell osteosarcoma tumour cases, 1 epithelioid sarcoma case, 1 leiomyosarcoma case, 1 fibrosarcoma case and 1 lymphoma case. According to the Enneking instalment, IB stage was found in 2 cases, IIA in 2 cases and IIB in 15 cases. A total of 3 patients underwent Malawer I resection, and 16 patients underwent Malawer II resection. The follow-up period was 11-174 months, with an average of 76.58 months. Local recurrence occurred in three patients and distant metastasis in seven patients; 4 patients succumbed and 15 survived. After biceps femoris tendon reconstruction and lateral collateral ligament insertion, 18 patients had good knee stability. The Musculoskeletal Tumour Society scale ranged between 23 and 29 points, with an average of 27.26 points; the Lysholm Knee Score was 65-84 points, with an average of 83 points. After the resection of proximal fibula primary and invasive tumours, the biceps femoris tendon and lateral collateral ligament insertion point was reconstructed. The data show that this technique can effectively reconstruct stability and restore knee function.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/cc/mco-18-04-02623.PMC9996172.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9453780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glyoxal-induced disruption of tumor cell progression in breast cancer. 乙二醛诱导的乳腺癌肿瘤细胞进展中断。
IF 1.2 Q3 Medicine Pub Date : 2023-04-01 DOI: 10.3892/mco.2023.2622
Pu Rong, Li Yanchu, Guo Nianchun, Li Qi, Li Xianyong

Breast cancer is the most common malignant tumor in women and remains a major global challenge, with ~1.4 million cases per year, worldwide. Numerous studies have shown that changes in cell metabolism are associated with the regulation of tumor progression. In the present study, the anti-cancer properties of glyoxal (GO), which is the smallest dialdehyde formed in the oxidation-reduction reaction and involved in electron transfer and energy metabolism, in breast cancer was investigated. The biological functions and molecular mechanisms of GO were investigated in breast cancer cell lines using MTT and crystal violet assays, flow cytometry, western blot analysis, 3D laser scanning confocal microscopy and transmission electron microscopy. The results showed that GO strongly inhibited cell proliferation, promoted cell apoptosis and cell cycle G2/M arrest, induced the disappearance of cellular microvilli, and enlarged mitochondria. In addition, the protein expression level of AKT, mTOR and p70-S6K decreased in the AKT-mTOR pathway, accompanied by an increase in p-ERK and p-MEK in the MAPK pathway. The results from the present study indicate that GO suppressed breast cancer progression via the MAPK and AKT-mTOR pathways. Taken together, these results provide the basis for a potential therapeutic strategy for breast cancer.

乳腺癌是女性中最常见的恶性肿瘤,仍然是一个重大的全球挑战,全世界每年约有140万例。大量研究表明,细胞代谢的变化与肿瘤进展的调控有关。在本研究中,我们研究了氧化还原反应中形成的最小的双醛(GO)在乳腺癌中的抗癌特性。采用MTT、结晶紫、流式细胞术、western blot、三维激光扫描共聚焦显微镜和透射电镜等方法研究氧化石墨烯在乳腺癌细胞株中的生物学功能和分子机制。结果表明,氧化石墨烯能强烈抑制细胞增殖,促进细胞凋亡和细胞周期G2/M阻滞,诱导细胞微绒毛消失,线粒体增大。此外,AKT-mTOR通路中AKT、mTOR和p70-S6K蛋白表达水平降低,MAPK通路中p-ERK和p-MEK蛋白表达水平升高。本研究的结果表明氧化石墨烯通过MAPK和AKT-mTOR途径抑制乳腺癌的进展。综上所述,这些结果为乳腺癌的潜在治疗策略提供了基础。
{"title":"Glyoxal-induced disruption of tumor cell progression in breast cancer.","authors":"Pu Rong,&nbsp;Li Yanchu,&nbsp;Guo Nianchun,&nbsp;Li Qi,&nbsp;Li Xianyong","doi":"10.3892/mco.2023.2622","DOIUrl":"https://doi.org/10.3892/mco.2023.2622","url":null,"abstract":"<p><p>Breast cancer is the most common malignant tumor in women and remains a major global challenge, with ~1.4 million cases per year, worldwide. Numerous studies have shown that changes in cell metabolism are associated with the regulation of tumor progression. In the present study, the anti-cancer properties of glyoxal (GO), which is the smallest dialdehyde formed in the oxidation-reduction reaction and involved in electron transfer and energy metabolism, in breast cancer was investigated. The biological functions and molecular mechanisms of GO were investigated in breast cancer cell lines using MTT and crystal violet assays, flow cytometry, western blot analysis, 3D laser scanning confocal microscopy and transmission electron microscopy. The results showed that GO strongly inhibited cell proliferation, promoted cell apoptosis and cell cycle G<sub>2</sub>/M arrest, induced the disappearance of cellular microvilli, and enlarged mitochondria. In addition, the protein expression level of AKT, mTOR and p70-S6K decreased in the AKT-mTOR pathway, accompanied by an increase in p-ERK and p-MEK in the MAPK pathway. The results from the present study indicate that GO suppressed breast cancer progression via the MAPK and AKT-mTOR pathways. Taken together, these results provide the basis for a potential therapeutic strategy for breast cancer.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/a4/mco-18-04-02622.PMC9993443.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9155699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chromophobe renal cell carcinoma with ipsilateral ureteral urothelial carcinoma: A case report. 嫌色性肾细胞癌合并同侧输尿管尿路上皮癌1例。
IF 1.2 Q3 Medicine Pub Date : 2023-04-01 DOI: 10.3892/mco.2023.2626
Peirui Wang, Ling Wang, Jiang Du, Guobiao Liang

It is very rare for different types of urological tumours to occur together, and it is even rarer for chromophobe renal cell carcinoma (CRCC) to be combined with ipsilateral ureteral urothelial carcinoma (UUC), and the symptoms are relatively homogeneous, mostly presenting as symptoms that can be observed in malignant tumours alone, and therefore are often easily missed. In the present study, a case of a patient who was admitted to the hospital for more than 3 months with no obvious cause of terminal carnivorous hematuria was reported, and ureteral carcinoma was considered in the preoperative diagnosis but not renal carcinoma. After completion of preoperative tests, laparoscopic right nephrectomy and right ureterectomy was performed. The postoperative pathological diagnosis was CRCC of the right side and low-grade UUC of the right side, and the patient did not show any significant abnormality at the postoperative follow-up. By discussing this case and reviewing the relevant literature, the present study provides clinicians with more insight.

不同类型的泌尿系统肿瘤同时发生的情况非常罕见,恐色性肾细胞癌(CRCC)与同侧输尿管尿路上皮癌(UUC)合并的情况更为罕见,且症状相对同质,多表现为恶性肿瘤单独出现的症状,容易被忽略。本研究报告1例患者入院3个月以上,无明显病因终末期肉食性血尿,术前诊断考虑输尿管癌,未考虑肾癌。术前检查完成后,行腹腔镜右肾切除术和右输尿管切除术。术后病理诊断为右侧CRCC,右侧低级别UUC,术后随访未见明显异常。通过对本病例的讨论和相关文献的回顾,本研究为临床医生提供了更多的见解。
{"title":"Chromophobe renal cell carcinoma with ipsilateral ureteral urothelial carcinoma: A case report.","authors":"Peirui Wang,&nbsp;Ling Wang,&nbsp;Jiang Du,&nbsp;Guobiao Liang","doi":"10.3892/mco.2023.2626","DOIUrl":"https://doi.org/10.3892/mco.2023.2626","url":null,"abstract":"<p><p>It is very rare for different types of urological tumours to occur together, and it is even rarer for chromophobe renal cell carcinoma (CRCC) to be combined with ipsilateral ureteral urothelial carcinoma (UUC), and the symptoms are relatively homogeneous, mostly presenting as symptoms that can be observed in malignant tumours alone, and therefore are often easily missed. In the present study, a case of a patient who was admitted to the hospital for more than 3 months with no obvious cause of terminal carnivorous hematuria was reported, and ureteral carcinoma was considered in the preoperative diagnosis but not renal carcinoma. After completion of preoperative tests, laparoscopic right nephrectomy and right ureterectomy was performed. The postoperative pathological diagnosis was CRCC of the right side and low-grade UUC of the right side, and the patient did not show any significant abnormality at the postoperative follow-up. By discussing this case and reviewing the relevant literature, the present study provides clinicians with more insight.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/33/21/mco-18-04-02626.PMC9995567.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9155696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia. 小肠腺癌的特点和结局:沙特阿拉伯一家三级医院14年的经验。
IF 1.2 Q3 Medicine Pub Date : 2023-03-01 DOI: 10.3892/mco.2023.2613
Bader Alshamsan, Mohamed Aseafan, Ahmed Badran, Amgad Shaheen, Mahmoud A Elshenawy, Shouki Bazarbashi, Ali H Aljubran

Small bowel adenocarcinoma (SBA) is an extremely rare cancer type. In the present study, the patient characteristics and clinical outcomes of patients diagnosed and treated for SBA at a single tertiary hospital were reported. All patients diagnosed and managed between 2007 and 2020 were reviewed. Regression analysis was used to assess variables associated with the metastatic stage at diagnosis. The Kaplan-Meier method was used to estimate survival and the log-rank test was used to determine factors associated with survival outcomes. Out of 137 cases of small bowel primary tumor, 43 consecutive patients with SBA were diagnosed with a median age of 53 years and the majority (76.7%) were males. The common initial presenting symptoms were abdominal pain (58.8%) and bowel obstruction (30.2%). The most common primary site was the duodenum (60.5%) and the majority (65.1%) were diagnosed with stage III/IV disease. Patients with a high neutrophil-lymphocyte ratio (NLR) (≥0.85) were more likely to be in the metastatic stage at diagnosis (P=0.01). The 3-year overall survival (OS) rates based on stage were 100% (I), 85% (II), 53% (III) and 33.9% (IV) (P=0.001). In addition to the stage, the Eastern Cooperative Oncology Group Performance Status (P<0.001), NLR (P<0.001), hypoalbuminemia (P=0.02) and chemotherapy in a metastatic setting (P=0.02) were prognostic factors for OS. In conclusion, NLR is a potential prognostic biomarker for a metastatic stage at diagnosis. Advanced stage, lower performance status score, low albumin level and high NLR are associated with short OS.

小肠腺癌(SBA)是一种极为罕见的癌症类型。在本研究中,报告了在一家三级医院诊断和治疗的SBA患者的患者特征和临床结果。回顾了2007年至2020年间诊断和治疗的所有患者。回归分析用于评估诊断时与转移阶段相关的变量。Kaplan-Meier法用于估计生存,log-rank检验用于确定与生存结果相关的因素。137例小肠原发肿瘤中,43例连续被诊断为SBA,中位年龄53岁,男性居多(76.7%)。常见的首发症状为腹痛(58.8%)和肠梗阻(30.2%)。最常见的原发部位是十二指肠(60.5%),大多数(65.1%)被诊断为III/IV期疾病。中性粒细胞-淋巴细胞比值(NLR)高(≥0.85)的患者在诊断时更有可能处于转移期(P=0.01)。基于分期的3年总生存率(OS)分别为100% (I)、85% (II)、53% (III)和33.9% (IV) (P=0.001)。除分期外,《东方肿瘤合作集团绩效状况》(P
{"title":"Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia.","authors":"Bader Alshamsan,&nbsp;Mohamed Aseafan,&nbsp;Ahmed Badran,&nbsp;Amgad Shaheen,&nbsp;Mahmoud A Elshenawy,&nbsp;Shouki Bazarbashi,&nbsp;Ali H Aljubran","doi":"10.3892/mco.2023.2613","DOIUrl":"https://doi.org/10.3892/mco.2023.2613","url":null,"abstract":"<p><p>Small bowel adenocarcinoma (SBA) is an extremely rare cancer type. In the present study, the patient characteristics and clinical outcomes of patients diagnosed and treated for SBA at a single tertiary hospital were reported. All patients diagnosed and managed between 2007 and 2020 were reviewed. Regression analysis was used to assess variables associated with the metastatic stage at diagnosis. The Kaplan-Meier method was used to estimate survival and the log-rank test was used to determine factors associated with survival outcomes. Out of 137 cases of small bowel primary tumor, 43 consecutive patients with SBA were diagnosed with a median age of 53 years and the majority (76.7%) were males. The common initial presenting symptoms were abdominal pain (58.8%) and bowel obstruction (30.2%). The most common primary site was the duodenum (60.5%) and the majority (65.1%) were diagnosed with stage III/IV disease. Patients with a high neutrophil-lymphocyte ratio (NLR) (≥0.85) were more likely to be in the metastatic stage at diagnosis (P=0.01). The 3-year overall survival (OS) rates based on stage were 100% (I), 85% (II), 53% (III) and 33.9% (IV) (P=0.001). In addition to the stage, the Eastern Cooperative Oncology Group Performance Status (P<0.001), NLR (P<0.001), hypoalbuminemia (P=0.02) and chemotherapy in a metastatic setting (P=0.02) were prognostic factors for OS. In conclusion, NLR is a potential prognostic biomarker for a metastatic stage at diagnosis. Advanced stage, lower performance status score, low albumin level and high NLR are associated with short OS.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/40/mco-18-03-02613.PMC9926043.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10742796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Gastric adenocarcinoma with high‑level microsatellite instability: A case report. 胃腺癌伴高水平微卫星不稳定性1例报告。
IF 1.2 Q3 Medicine Pub Date : 2023-03-01 DOI: 10.3892/mco.2023.2612
Alejandro Alfaro, Daniel Zanabria, Alfredo Aguilar, Sergio A Jimenez-Solano, Alejandra Zevallos, Williams Fajardo

Gastric cancer (GC) ranks fifth on the list of the most common malignancies worldwide. In Peru, gastric neoplasms are considered the second leading cause of mortality among males. Among the molecular subgroups of GC, microsatellite instability presents a favorable prognosis due to its hypermutated phenotype, which activates immunosurveillance. The present study describes the case of a 75-year-old patient, who was admitted in the hospital with a history of upper gastrointestinal bleeding and recurrent hospital admission, due to severe anemia. The patient presented with pale skin, normal vital functions, slight swelling of the lower extremities, and abdominal distention and bloating upon a physical examination. An endoscopic examination revealed an infiltrating circular ulcerated lesion. The histopathological analysis identified a moderately differentiated intestinal-type adenocarcinoma with pathological stage T3N0M0. Tumor genomic profiling demonstrated alterations in 15 different genes with a tumor mutational burden of 28 mutations/Mb. Finally, the patient underwent a partial gastrectomy without pre-operative chemotherapy. After 4 days, the patient presented with post-operative complications for which he was re-operated on. The patient did not survive. To the best of our knowledge, in the present case, pernicious anemia was an early sign of GC and a gastroscopy had to be performed. Furthermore, MutS homolog 3 alterations probably conditioned the presence of multiple frame-shift mutations.

胃癌(GC)在全球最常见的恶性肿瘤中排名第五。在秘鲁,胃肿瘤被认为是男性死亡的第二大原因。在GC的分子亚群中,微卫星不稳定性由于其超突变的表型而具有良好的预后,可激活免疫监测。本研究描述了一名75岁患者的病例,他因严重贫血而入院,有上消化道出血和反复住院的病史。患者体检时皮肤苍白,生命功能正常,下肢轻度肿胀,腹胀腹胀。内窥镜检查显示浸润性圆形溃疡病变。组织病理学分析确定为中分化肠型腺癌,病理分期为T3N0M0。肿瘤基因组分析显示15个不同基因的改变,肿瘤突变负荷为28个突变/Mb。最后,患者接受了部分胃切除术,没有术前化疗。4天后,患者出现术后并发症,再次手术。病人没能活下来。据我们所知,在本病例中,恶性贫血是胃癌的早期征兆,必须进行胃镜检查。此外,MutS同源3的改变可能制约了多个帧移突变的存在。
{"title":"Gastric adenocarcinoma with high‑level microsatellite instability: A case report.","authors":"Alejandro Alfaro,&nbsp;Daniel Zanabria,&nbsp;Alfredo Aguilar,&nbsp;Sergio A Jimenez-Solano,&nbsp;Alejandra Zevallos,&nbsp;Williams Fajardo","doi":"10.3892/mco.2023.2612","DOIUrl":"https://doi.org/10.3892/mco.2023.2612","url":null,"abstract":"<p><p>Gastric cancer (GC) ranks fifth on the list of the most common malignancies worldwide. In Peru, gastric neoplasms are considered the second leading cause of mortality among males. Among the molecular subgroups of GC, microsatellite instability presents a favorable prognosis due to its hypermutated phenotype, which activates immunosurveillance. The present study describes the case of a 75-year-old patient, who was admitted in the hospital with a history of upper gastrointestinal bleeding and recurrent hospital admission, due to severe anemia. The patient presented with pale skin, normal vital functions, slight swelling of the lower extremities, and abdominal distention and bloating upon a physical examination. An endoscopic examination revealed an infiltrating circular ulcerated lesion. The histopathological analysis identified a moderately differentiated intestinal-type adenocarcinoma with pathological stage T3N0M0. Tumor genomic profiling demonstrated alterations in 15 different genes with a tumor mutational burden of 28 mutations/Mb. Finally, the patient underwent a partial gastrectomy without pre-operative chemotherapy. After 4 days, the patient presented with post-operative complications for which he was re-operated on. The patient did not survive. To the best of our knowledge, in the present case, pernicious anemia was an early sign of GC and a gastroscopy had to be performed. Furthermore, MutS homolog 3 alterations probably conditioned the presence of multiple frame-shift mutations.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10742797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stathmin1 promotes lymph node metastasis in hypopharyngeal squamous cell carcinoma via regulation of HIF‑1α/VEGF‑A axis and MTA1 expression. Stathmin1通过调控HIF - 1α/VEGF - A轴和MTA1表达促进下咽鳞状细胞癌的淋巴结转移。
IF 1.2 Q3 Medicine Pub Date : 2023-03-01 DOI: 10.3892/mco.2023.2617
Yuqian Wu, Qin Liu, Jiaojiao Tong, Chunhui Hu, Dianshui Sun

Extensive neck lymph node metastasis (LNM) is an important clinical feature of hypopharyngeal squamous cell carcinoma (HSCC). Stathmin1 (STMN1) is closely associated with LNM in numerous human cancers. In the present study, the association between STMN1 and neck LNM in HSCC and the underlying molecular mechanisms were explored. First, postoperative samples of HSCC were screened and the association between STMN1 and neck LNM in HSCC was analyzed. Then, cell functional experiments were performed to assess the potential of STMN1 to promote invasion and migration. Subsequently, the potential target genes and pathways of STMN1 were predicted using bioinformatics analysis. Finally, the obtained target genes and pathways of STMN1 were validated by reverse transcription-quantitative PCR (RT-qPCR) and western blot analyses to confirm the potential mechanisms by which STMN1 promotes LNM in HSCC. As a result, a total of 117 postoperative samples of HSCC were screened, and STMN1 was proven to be associated with neck LNM in HSCC. Further, cell functional experiments established that high expression of STMN1 could actually promote FaDu cell invasion and metastasis. Bioinformatics analysis revealed that high expression of STMN1 was associated with the activation of hypoxia inducible factor-1alpha (HIF-1α) pathway and increased expression of metastasis-associated protein 1 (MTA1). Finally, RT-qPCR and western blot analyses confirmed that STMN1 promotes the expression levels of HIF-1α/vascular endothelial growth factor (VEGF)-A and MTA1 in FaDu cell lines. In conclusion, it was found that high expression of STMN1 promoted neck LNM in HSCC and the potential mechanisms may be via regulation of the HIF-1α/VEGF-A axis and MTA1 expression.

颈部广泛淋巴结转移是下咽鳞状细胞癌的重要临床特征。Stathmin1 (STMN1)在许多人类癌症中与LNM密切相关。在本研究中,我们探讨了STMN1与hsc颈部LNM之间的关系及其潜在的分子机制。首先,筛选术后HSCC样本,分析STMN1与HSCC颈部淋巴结转移的关系。然后,进行细胞功能实验以评估STMN1促进侵袭和迁移的潜力。随后,利用生物信息学分析预测STMN1的潜在靶基因和通路。最后,通过逆转录定量PCR (RT-qPCR)和western blot分析验证STMN1的靶基因和通路,以确定STMN1促进hsc中LNM的潜在机制。结果,共筛选了117例术后HSCC样本,证实STMN1与HSCC颈部淋巴结转移相关。此外,细胞功能实验证实,高表达STMN1确实可以促进FaDu细胞的侵袭和转移。生物信息学分析显示,STMN1的高表达与缺氧诱导因子-1α (HIF-1α)通路激活和转移相关蛋白1 (MTA1)表达增加有关。最后,RT-qPCR和western blot分析证实,STMN1可促进FaDu细胞株中HIF-1α/血管内皮生长因子(VEGF)-A和MTA1的表达水平。综上所述,我们发现STMN1的高表达促进了HSCC颈部LNM的发生,其潜在机制可能是通过调控HIF-1α/VEGF-A轴和MTA1的表达。
{"title":"Stathmin1 promotes lymph node metastasis in hypopharyngeal squamous cell carcinoma via regulation of HIF‑1α/VEGF‑A axis and MTA1 expression.","authors":"Yuqian Wu,&nbsp;Qin Liu,&nbsp;Jiaojiao Tong,&nbsp;Chunhui Hu,&nbsp;Dianshui Sun","doi":"10.3892/mco.2023.2617","DOIUrl":"https://doi.org/10.3892/mco.2023.2617","url":null,"abstract":"<p><p>Extensive neck lymph node metastasis (LNM) is an important clinical feature of hypopharyngeal squamous cell carcinoma (HSCC). Stathmin1 (STMN1) is closely associated with LNM in numerous human cancers. In the present study, the association between STMN1 and neck LNM in HSCC and the underlying molecular mechanisms were explored. First, postoperative samples of HSCC were screened and the association between STMN1 and neck LNM in HSCC was analyzed. Then, cell functional experiments were performed to assess the potential of STMN1 to promote invasion and migration. Subsequently, the potential target genes and pathways of STMN1 were predicted using bioinformatics analysis. Finally, the obtained target genes and pathways of STMN1 were validated by reverse transcription-quantitative PCR (RT-qPCR) and western blot analyses to confirm the potential mechanisms by which STMN1 promotes LNM in HSCC. As a result, a total of 117 postoperative samples of HSCC were screened, and STMN1 was proven to be associated with neck LNM in HSCC. Further, cell functional experiments established that high expression of STMN1 could actually promote FaDu cell invasion and metastasis. Bioinformatics analysis revealed that high expression of STMN1 was associated with the activation of hypoxia inducible factor-1alpha (HIF-1α) pathway and increased expression of metastasis-associated protein 1 (MTA1). Finally, RT-qPCR and western blot analyses confirmed that STMN1 promotes the expression levels of HIF-1α/vascular endothelial growth factor (VEGF)-A and MTA1 in FaDu cell lines. In conclusion, it was found that high expression of STMN1 promoted neck LNM in HSCC and the potential mechanisms may be via regulation of the HIF-1α/VEGF-A axis and MTA1 expression.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bc/ff/mco-18-03-02617.PMC9944248.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10792395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pan‑cancer analysis of the deoxyribonuclease gene family. 脱氧核糖核酸酶基因家族的泛癌分析。
IF 1.2 Q3 Medicine Pub Date : 2023-03-01 DOI: 10.3892/mco.2023.2615
Qingquan Bai, Xiao He, Tianhui Hu

Deoxyribonuclease (DNase) is an enzyme that catalyzes the cleavage of phosphodiester bonds in the main chain of DNA to degrade DNA. DNase serves a vital role in several immune-related diseases. The present study linked the expression of DNase with overall survival (OS), performed pan-cancer co-expression analysis, and assessed the association between DNase and immune infiltration subtypes, tumor microenvironment and drug sensitivity through pan-cancer studies. Furthermore, gene expression data and clinical data were downloaded from The Cancer Genome Atlas. Next, through a series of bioinformatics analyses, DNase expression and survival, immune subtypes, tumor microenvironment and drug sensitivity in 33 tumor types were systematically studied. The expression of the DNase gene family was shown to have an apparent intratumoral heterogeneity. The expression of DNase 2, lysosomal (DNASE2) was the highest in tumors, whereas that of DNASE2 β was the lowest. DNase 1-like 3 (DNASE1L3) was mainly downregulated in tumors, whereas the rest of the DNases were mainly upregulated in tumors. The expression of DNase family members was also found to be associated with the OS rate of patients. DNase family genes may serve an essential role in the tumor microenvironment. DNase family gene expression was related to the content of cytotoxic cells, Immunescore, Stromalscore, Estimatescore and Tumorpurity. The present study also revealed that the DNase genes may be involved in the drug resistance of cancer cells. Finally, the correlation between DNase, and clinical stage and tumor microenvironment in hepatocellular carcinoma (HCC) was studied. In addition, the difference in DNASE1L3 expression between HCC and adjacent normal tissues, and the relationship between DNASE1L3 expression and clinical stage was verified by analyzing three groups in a Gene Expression Omnibus dataset and by performing immunohistochemistry. In conclusion, the present study assessed DNase gene expression, analyzed its relationship with patient OS, performed pan-cancer co-expression analysis, and assessed the association between DNase and immune infiltration subtypes, tumor microenvironment and drug sensitivity. The present study also confirmed the value of further laboratory research on DNases and their prospects in clinical cancer treatment.

脱氧核糖核酸酶(DNase)是一种催化DNA主链上磷酸二酯键裂解以降解DNA的酶。DNase在几种免疫相关疾病中起着至关重要的作用。本研究将DNase的表达与总生存率(OS)联系起来,进行泛癌共表达分析,并通过泛癌研究评估DNase与免疫浸润亚型、肿瘤微环境和药物敏感性的关系。此外,从The Cancer Genome Atlas下载基因表达数据和临床数据。接下来,通过一系列生物信息学分析,系统研究了33种肿瘤中DNase的表达和存活、免疫亚型、肿瘤微环境和药物敏感性。dna酶基因家族的表达在肿瘤内具有明显的异质性。肿瘤组织中dna酶2、溶酶体(DNASE2)表达量最高,而DNASE2 β表达量最低。DNase 1-like 3 (DNASE1L3)在肿瘤中主要下调,其余DNase在肿瘤中主要上调。DNase家族成员的表达也与患者的OS率相关。dna酶家族基因可能在肿瘤微环境中起重要作用。DNase家族基因表达与细胞毒性细胞含量、免疫评分、基质评分、估计评分和肿瘤纯度有关。本研究还揭示了dna酶基因可能参与了癌细胞的耐药过程。最后,探讨DNase与肝细胞癌(HCC)临床分期及肿瘤微环境的相关性。此外,通过分析基因表达Omnibus数据集中的三组并进行免疫组化,验证了肝癌与邻近正常组织中DNASE1L3表达的差异,以及DNASE1L3表达与临床分期的关系。综上所述,本研究评估了DNase基因表达,分析了其与患者OS的关系,进行了泛癌共表达分析,评估了DNase与免疫浸润亚型、肿瘤微环境和药物敏感性的关系。本研究也证实了进一步实验室研究dna酶的价值及其在临床癌症治疗中的前景。
{"title":"Pan‑cancer analysis of the deoxyribonuclease gene family.","authors":"Qingquan Bai,&nbsp;Xiao He,&nbsp;Tianhui Hu","doi":"10.3892/mco.2023.2615","DOIUrl":"https://doi.org/10.3892/mco.2023.2615","url":null,"abstract":"<p><p>Deoxyribonuclease (DNase) is an enzyme that catalyzes the cleavage of phosphodiester bonds in the main chain of DNA to degrade DNA. DNase serves a vital role in several immune-related diseases. The present study linked the expression of DNase with overall survival (OS), performed pan-cancer co-expression analysis, and assessed the association between DNase and immune infiltration subtypes, tumor microenvironment and drug sensitivity through pan-cancer studies. Furthermore, gene expression data and clinical data were downloaded from The Cancer Genome Atlas. Next, through a series of bioinformatics analyses, DNase expression and survival, immune subtypes, tumor microenvironment and drug sensitivity in 33 tumor types were systematically studied. The expression of the DNase gene family was shown to have an apparent intratumoral heterogeneity. The expression of DNase 2, lysosomal (DNASE2) was the highest in tumors, whereas that of DNASE2 β was the lowest. DNase 1-like 3 (DNASE1L3) was mainly downregulated in tumors, whereas the rest of the DNases were mainly upregulated in tumors. The expression of DNase family members was also found to be associated with the OS rate of patients. DNase family genes may serve an essential role in the tumor microenvironment. DNase family gene expression was related to the content of cytotoxic cells, Immunescore, Stromalscore, Estimatescore and Tumorpurity. The present study also revealed that the DNase genes may be involved in the drug resistance of cancer cells. Finally, the correlation between DNase, and clinical stage and tumor microenvironment in hepatocellular carcinoma (HCC) was studied. In addition, the difference in DNASE1L3 expression between HCC and adjacent normal tissues, and the relationship between DNASE1L3 expression and clinical stage was verified by analyzing three groups in a Gene Expression Omnibus dataset and by performing immunohistochemistry. In conclusion, the present study assessed DNase gene expression, analyzed its relationship with patient OS, performed pan-cancer co-expression analysis, and assessed the association between DNase and immune infiltration subtypes, tumor microenvironment and drug sensitivity. The present study also confirmed the value of further laboratory research on DNases and their prospects in clinical cancer treatment.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/a6/mco-18-03-02615.PMC9926046.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10742794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of miR‑200 family in brain metastases: A systematic review. miR - 200家族在脑转移中的作用:一项系统综述
IF 1.2 Q3 Medicine Pub Date : 2023-03-01 DOI: 10.3892/mco.2023.2611
George Fotakopoulos, Vasiliki Epameinondas Georgakopoulou, Demetrios A Spandidos, Petros Papalexis, Efthalia Angelopoulou, Aikaterini Aravantinou-Fatorou, Nikolaos Trakas, Ilias Trakas, Alexandros G Brotis

Brain metastasis (BM) represents the single most severe neurological complication of systemic cancer. The prognosis of patients with BM is poor, irrespective of the implemented treatment. The present study performed a systematic review of the literature using three online databases (PubMed, Scopus and Web of Science). Recently, a number of small RNA molecules, the microRNAs (miRNAs/miRs), have attracted increasing scientific attention. Members of the miR-200 family, which includes five miRNAs (miR-141, miR-200a, miR-200b, miR-200c and miR-429) appear to play pivotal roles in cancer initiation and metastasis. Indeed, a systematic review of the pertinent literature revealed that miR-200 family members regulate the brain metastatic cascade, particularly by modulating epithelial-to-mesenchymal transition. That holds true for the major representatives of BM, including lung and breast cancer, as well as for other less frequent secondary lesions originating from melanoma and the gastrointestinal tract. Therefore, the miRNAs may serve as potential diagnostic and/or prognostic markers, and under specific circumstances, as invaluable therapeutic targets. However, the available clinical evidence is relatively limited. A number of studies have suggested that the miR-200 family members are accurate prognostic markers of survival and resistance to chemotherapy in patients with breast cancer. Similarly, they may prove helpful in differentiating a metastatic lesion from a malignant glioma, or a hemangioblastoma from a renal cell carcinoma in patients with von Hippel Lindau syndrome, based on a cerebrospinal fluid sample. However, currently, there is no known therapeutic role for miR-200 family members in the setting of BM.

脑转移(BM)是系统性癌症最严重的神经系统并发症。无论实施何种治疗,BM患者的预后都很差。本研究使用三个在线数据库(PubMed、Scopus和Web of Science)对文献进行了系统的综述。近年来,一些小RNA分子,即microRNAs (miRNAs/miRs),引起了越来越多的科学关注。miR-200家族的成员,包括5个mirna (miR-141、miR-200a、miR-200b、miR-200c和miR-429),似乎在癌症的发生和转移中发挥关键作用。事实上,对相关文献的系统回顾显示,miR-200家族成员调节脑转移级联反应,特别是通过调节上皮细胞到间质细胞的转变。这适用于BM的主要代表,包括肺癌和乳腺癌,以及其他不太常见的源于黑色素瘤和胃肠道的继发性病变。因此,mirna可以作为潜在的诊断和/或预后标志物,并在特定情况下作为宝贵的治疗靶点。然而,现有的临床证据相对有限。许多研究表明,miR-200家族成员是乳腺癌患者生存和化疗耐药的准确预后标志物。同样,根据脑脊液样本,它们可能有助于区分转移性病变与恶性胶质瘤,或血管母细胞瘤与肾细胞癌。然而,目前还没有发现miR-200家族成员在BM中的治疗作用。
{"title":"Role of miR‑200 family in brain metastases: A systematic review.","authors":"George Fotakopoulos,&nbsp;Vasiliki Epameinondas Georgakopoulou,&nbsp;Demetrios A Spandidos,&nbsp;Petros Papalexis,&nbsp;Efthalia Angelopoulou,&nbsp;Aikaterini Aravantinou-Fatorou,&nbsp;Nikolaos Trakas,&nbsp;Ilias Trakas,&nbsp;Alexandros G Brotis","doi":"10.3892/mco.2023.2611","DOIUrl":"https://doi.org/10.3892/mco.2023.2611","url":null,"abstract":"<p><p>Brain metastasis (BM) represents the single most severe neurological complication of systemic cancer. The prognosis of patients with BM is poor, irrespective of the implemented treatment. The present study performed a systematic review of the literature using three online databases (PubMed, Scopus and Web of Science). Recently, a number of small RNA molecules, the microRNAs (miRNAs/miRs), have attracted increasing scientific attention. Members of the miR-200 family, which includes five miRNAs (miR-141, miR-200a, miR-200b, miR-200c and miR-429) appear to play pivotal roles in cancer initiation and metastasis. Indeed, a systematic review of the pertinent literature revealed that miR-200 family members regulate the brain metastatic cascade, particularly by modulating epithelial-to-mesenchymal transition. That holds true for the major representatives of BM, including lung and breast cancer, as well as for other less frequent secondary lesions originating from melanoma and the gastrointestinal tract. Therefore, the miRNAs may serve as potential diagnostic and/or prognostic markers, and under specific circumstances, as invaluable therapeutic targets. However, the available clinical evidence is relatively limited. A number of studies have suggested that the miR-200 family members are accurate prognostic markers of survival and resistance to chemotherapy in patients with breast cancer. Similarly, they may prove helpful in differentiating a metastatic lesion from a malignant glioma, or a hemangioblastoma from a renal cell carcinoma in patients with von Hippel Lindau syndrome, based on a cerebrospinal fluid sample. However, currently, there is no known therapeutic role for miR-200 family members in the setting of BM.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4a/ec/mco-18-03-02611.PMC9926042.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10742795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Molecular and clinical oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1